GlassScriptPhysician profile
Joseph N Chipman
NPI 1871756759
$118,172.75
in general payments reported to CMS, 2019-2025
8 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $14K · 2021: $20K · 2022: $17K · 2023: $15K · 2024: $6,776 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Consulting Fee: $1,680 · Travel and Lodging: $884 · Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,655.00 |
| Consulting Fee | $1,680.00 |
| Travel and Lodging | $883.94 |
| Food and Beverage | $627.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $42,515.59 | 2022-2025 | Botox |
| Alexion Pharmaceuticals, INC. | $35,100.64 | 2019-2023 | Ultomiris |
| Allergan, INC. | $32,049.48 | 2019-2021 | |
| Amgen INC. | $4,112.32 | 2025 | |
| Ucb, INC. | $3,360.00 | 2024 | Rystiggo, Zilbrysq |
| Akcea Therapeutics, INC. | $571.16 | 2020-2021 | |
| Argenx US, INC. | $325.00 | 2022 | |
| Nevro Corp. | $138.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Chipman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.